Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

Pharmaceutical companies are responsible for providing accurate, balanced, non-promotional information about their products to both patients and healthcare providers. In these points of contact, ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

Roger Cone, Ph.D., a professor at the University of Michigan and the founder and chair of the scientific advisory board at Courage Therapeutics, has been thinking about the biological mechanics of ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

The Business of Biotech was taped in front of a live audience in Boston during the BIO conference last month, and we couldn’t have asked for a better guest to test out this new format. Amber Salzman, ...

I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...